Skip to main content

Dr. David E. Stickler, MD

Neurology (Neurology Physician)

  • Medicare participating

At a glance

Years since graduation
27
In the NPI registry since
2006
Medicare patients seen, 2024
432

The NPI date is when this clinician registered for a National Provider Identifier, the billing number used on health claims. It is not a license, graduation or board-certification date. NPIs were first issued in May 2005 and became required on claims in 2007–2008, so an early date usually means the clinician was already in practice before then. What an NPI is

Education and training

  • 1999Medical school: West Virginia University School of Medicine
  • 2006Registered with an NPI (national billing number; not a license date) — NPIs began in 2005, so practice likely started earlier

Undergraduate school, residency, fellowship, licensing exams and board certification aren’t in public federal data. Board certification can be confirmed with the certifying board (ABMS member boards for MDs, AOA boards for DOs).

Specialties and state licenses

  • Neurology Physician primary
    SC license 28323

As reported to the NPI registry. To confirm a license is current, check the state medical board.

Map: Neurology per capita by county →

Where they work

Hospitals

Medical groups

Hospitals this clinician lists with Medicare, and groups they bill Medicare through (Care Compare). Affiliation doesn’t mean they see patients at every location.

Medicare patients and services

Medicare patients, 2024
432
Services billed
1,042
Patients’ average age
73
Most frequent Medicare services, 2023
ServiceTimesPatients
Needle measurement of electrical activity in arm or leg muscles, complete study391242
Established patient office or other outpatient visit, 20-29 minutes315209
Established patient office or other outpatient visit, 30-39 minutes9469
Nerve conduction, 5-6 studies6868
Nerve conduction, 3-4 studies6666
Needle measurement of electrical activity in arm or leg muscles, limited study5444
New patient office or other outpatient visit, 30-44 minutes4949
Nerve conduction, 7-8 studies4747
Nerve conduction, 13 or more studies2828
Nerve conduction, 9-10 studies2727

Medicare fee-for-service only. CMS leaves out services billed for fewer than 11 patients. These figures describe a practice’s Medicare work; they aren’t a measure of quality.

Medicare prescriptions

Prescriptions filled under Medicare Part D, including refills. CMS leaves out drugs prescribed fewer than 11 times.

Payments from drug and device companies

In 2025, 1 companies reported 1 payments worth $124 in total to this clinician.

By company
AbbVie Inc.$124
By type
Food and Beverage$124

From CMS Open Payments. A payment is not evidence of wrongdoing; many are for consulting, teaching or meals. Clinicians can review and dispute their records with CMS.

Who received the most in South Carolina →

Industry-funded research

Named as a principal investigator on 9 industry-funded studies in 2025, from 5 companies. The companies reported $314,943 in research payments for these studies, mostly to the institutions running them.

  • A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy
    Vertex Pharmaceuticals Incorporated
  • A Phase 3, Randomized, Double-Blind, Placebo-Controlled, 3-Arm, 3-Period Study to assess the Efficacy and Safety of a New Formulation of Oral Cladribine compared with Placebo in Participants with Generalized Myastheni…
    Ares Trading SA
  • A Phase 3, Open-label Study Evaluating the Long-term Safety and Effectiveness of Suzetrigine in Subjects With Pain Associated With Diabetic Peripheral Neuropathy
    Vertex Pharmaceuticals Incorporated
  • LX9211.1-204-DPN
    Lexicon Pharmaceuticals, Inc.
  • A Phase 3, Randomized, Double blind, Placebo controlled, Parallel, Multicenter Study to Evaluate the Safety and Efficacy of ALXN1720 in Adults with Generalized Myasthenia Gravis
    Alexion Pharmaceuticals, Inc.
  • Study name not reported
    Lexicon Pharmaceuticals, Inc.
  • Study of BOTOX Injections in Prevention of Migraine in Adult Participants With Episodic Migraine
    AbbVie Inc. · Terminated · NCT05028569
  • A Phase 2b/3 Adaptive, Randomized, Placebo-controlled, Double-blind Study Evaluating the Efficacy, Safety and Tolerability of Povetacicept for Treatment of Generalized Myasthenia Gravis
    Vertex Pharmaceuticals Incorporated
  • A Phase 3, Randomized, Double-blind, Placebo-controlled, Parallel-design Study of the Efficacy and Safety of Suzetrigine in Subjects With Painful Diabetic Peripheral Neuropathy?
    Vertex Pharmaceuticals Incorporated

From CMS Open Payments research payments, where companies name up to five principal investigators per payment. Research payments usually go to hospitals, universities and research sites, not to the investigator personally. A payment is not evidence of wrongdoing.

Sources

NPI registry (CMS NPPES, November 2026; record last updated March 18, 2014), Medicare Care Compare, Medicare Physician & Other Practitioners (2024), Medicare Part D Prescribers (2024) and Open Payments (2025). Information is self-reported or billed data and may be out of date; call before visiting.

NPI 1699711945. Official NPI registry record (opens in a new tab). Clinicians can correct their information in NPPES; changes appear here after our next monthly update.